44 results about "Neurturin" patented technology

The present invention concerns methods and compositions for gene therapy, in particular in vivo gene therapy for delivery of bioactive Neurturin for the treatment of Parkinson's Disease. In another aspect the invention relates to virus expression constructs comprising a mammalian signal peptide linked to a mature or N-terminally truncated Neurturin without a functional pro-region between the signal peptide and the Neurturin. These viral expression constructs are required for efficient secretion of bioactive Neurturin in in vivo gene therapy. The invention also concerns mammalian cells capable of producing Neurturin in increased amounts as well as the use of these cells for recombinant production of bioactive Neurturin and for therapeutic use.

A neurotrophin production/secretion promoting agent which comprises an azole derivative of the formula:wherein R1 represents a halogen atom, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, a thiol group which may optionally be substituted, or an amino group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; X represents oxygen atom, sulfur atom, or nitrogen atom which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof; which is useful as an agent for preventing or treating neuropathy.

NTNRalpha, NTNRalpha extracellular domain (ECD), NTNRalpha variants, chimeric NTNRalpha (e.g., NTNRalpha immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNRalpha-ligands, for example NTN, by providing NTNRalpha to the cell.

Described herein is a system which uses a gene therapy particle that includes at least one gene, cDNA, fragment or analogue of at least one neurotropin that binds to the trkB receptor or the trkB receptor itself. The gene therapy particle is capable of being delivered to a subject in need thereof for therapy of a metabolic disorder. In a particular aspect, this invention is directed to an inventive method that demonstrates a remarkable efficacy on lowering body weight.

The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.

The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.

The invention discloses a nerve regeneration gel as well as a preparation method and application thereof. The matrix of the nerve regeneration gel is formed by fibrinogen, thrombin, laminin and fibronectin; the nerve regeneration gel contains procyanidine, sonic hedgehog, an epidermal growth factor, neurenergen-3 and a vascular endothelial growth factor. In-vitro test and animal test show that thegel is capable of accelerating neuron regeneration and neurite extension and repairing the injured nerve tissue. The matrix of the gel comprises fibrin, laminin and fibronectin and is capable of reducing formation of cavities and accelerating adhesion and proliferation of endogenous neural stem cells; the procyanidine in the gel is capable of resisting oxidation and inhibiting inflammation; the sonic hedgehog, the epidermal growth factor and the neurenergen-3 are capable of accelerating proliferation of the stem cells and differentiation to neurons of the stem cells; the vascular endothelialgrowth factor is capable of accelerating generation of blood vessels. The gel can be formed in situ on injured parts and can be used for treating nervous system injury.

The present invention relates to the construction method and application of one kind of human neurenergen-3 receptor gene (human TrkC gene) recombined adenovirus expressing vector. The basic scheme of the present invention includes: designing and synthesizing primer, RT-PCR process, construction and identification of cloned shuttle vector pShuttle-TrkC, construction and identification of recombined adenovirus vector pAdeno-TrkC, 293 cell packaging, identification of recombined adenovirus, bioactivity detection of human neurenergen-3 receptor gene recombined adenovirus expressing vector and other steps. The present invention is superior in that one kind gene recombined adenovirus expressing vector is selected to promote the survival of damaged central neure and the regeneration of axone, to promote nerve stem cell to differentiate into more neures to replace damaged or dead neures.

The invention discloses a method for preparing tissue engineering spinal cords by using mesenchymal stem cells derived from dermis, which comprises the following steps of 1) separating dMSCs, and carrying out passage on the dMSCs so as to obtain dMSCs primary cells; 2) moving the dMSCs primary cells obtained through separating to an amplification culture medium so as to carry out amplification; and 3) dropwise adding an engineering spinal cord saturated water solution into a physiological saline solution containing deep nerve nutriments, retinoic acid and Neuregulin, standing the obtained mixture, carrying out gradient alcohol dehydration on the mixture, and carrying out vacuum drying on the mixture; and infecting the dMSCs subjected to amplification by using a brain-derived neurenergen adenovirus expression vector, and inoculating cells to an engineering spinal cord material for culturing. In the method, tissue engineering spinal cords can effectively promote cell proliferation; and the differentiation rates of the tissue engineering spinal cords to nerve cells and oligodendroglia cells are respectively about 4.8% and 1.5% which are far higher than those of pure scaffold materials (the differentiation rates of pure scaffold materials to nerve cells and oligodendroglia cells are respectively 1.8% and 0.5%).

The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability.

The invention relates to a biological activity of an adenovirus expression vector which is recombined by using a human neurotrophin-3 receptor gene (human TrkC gene) and an application in the nerve injury repair thereof. The human Ad-TrkC can be used for promoting the survival of the injured central neurons and the axonal regeneration, so as to promote the neural stem cells to be more divided into the neurons with the potential of synaptic formation, further to replace the injured neurons or the dead neurons. The biological activity strengthens the protection mechanism of the central nervous system after the injury on the gene treatment level, replaces the injured neurons, participates in the reconstruction of the neural network and repairs the functions of the central nervous. Thus, the application has important significances for prolonging the human life, improving the quality of lives of the wounds and the patients, reducing the social and the family burdens and promoting the development of Chinese socioeconomic development.

The invention relates to compounds of Formula I:

and pharmaceutically acceptable salts and prodrugs thereof, wherein R₁, R₂, and R₃ are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.

The invention relates to a construction method of a controlled-release TrkC receptor ligand-NT-3 (neurotrophin-3) gelatin sponge cylinder bracket for repairing the spinal cord injury, particularly to a construction method of a controlled-release TrkC receptor ligand gelatin sponge bracket material containing overexpression TrkC receptor cells. During application, the controlled-release TrkC receptor ligand gelatin sponge cylinder bracket with the overexpression TrkC receptor cells and differentiated cells of the overexpression TrkC receptor cells implanted is transplanted to a cross-sectional spinal cord injury position and can better promote regeneration and function repair of injured nervous centralis. The construction method has great significance in enhancement of protection of injured nerve cells after the cross-sectional spinal cord injury at the biological tissue engineering level, promotion of axonal regeneration of the nerve cells, improvement on the quality of life of the sick and the injured, reduction of social and family burdens and promotion of social and economic development in China.

The invention discloses a method for preparing a tissue engineering spinal cord by using ancestral cells originated from skin. The method comprises the following steps: 1) separating SKPs, and passing to obtain SKPs primary cells; 2) immigrating the SKPs primary cells separated to an amplification culture medium for amplification; and 3) preparing the tissue engineering spinal cord, and dropwise adding saturated aqueous liquor of a tissue engineering spinal cord material to physiological saline liquor containing Neurotrophin-3(NT3), retinoic acid and Neuregulin; infecting the amplified SKPs by a brain-derived neurenergen adenovirus expression vector, and inoculating the cells to the tissue engineering spinal cord material to cultivate. In the method disclosed by the invention, the tissue engineering spinal cord can effectively promote cell proliferation, and the differentiating proportions of the tissue engineering spinal cord toward nerve cells and oligodendroglia cells are about 4.8% and 1.5% which are far greater than 1.8% and 0.5% of a pure support material.